• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定义与帕金森病相关的外显率的分子机制。

Molecular mechanisms defining penetrance of -associated Parkinson's disease.

作者信息

Trinh Joanne, Schymanski Emma L, Smajic Semra, Kasten Meike, Sammler Esther, Grünewald Anne

机构信息

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

出版信息

Med Genet. 2022 Aug 12;34(2):103-116. doi: 10.1515/medgen-2022-2127. eCollection 2022 Jun.

DOI:10.1515/medgen-2022-2127
PMID:38835904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11006382/
Abstract

Mutations in () are the most frequent cause of dominantly inherited Parkinson's disease (PD). mutations, among which p.G2019S is the most frequent, are inherited with reduced penetrance. Interestingly, the disease risk associated with G2019S can vary dramatically depending on the ethnic background of the carrier. While this would suggest a genetic component in the definition of -PD penetrance, only few variants have been shown to modify the age at onset of patients harbouring mutations, and the exact cellular pathways controlling the transition from a healthy to a diseased state currently remain elusive. In light of this knowledge gap, recent studies also explored environmental and lifestyle factors as potential modifiers of -PD. In this article, we (i) describe the clinical characteristics of mutation carriers, (ii) review known genes linked to -PD onset and (iii) summarize the cellular functions of with particular emphasis on potential penetrance-related molecular mechanisms. This section covers 's involvement in Rab GTPase and immune signalling as well as in the regulation of mitochondrial homeostasis and dynamics. Additionally, we explored the literature with regard to (iv) lifestyle and (v) environmental factors that may influence the penetrance of mutations, with a view towards further exposomics studies. Finally, based on this comprehensive overview, we propose potential future , and studies that could provide a better understanding of the processes triggering PD in individuals with mutations.

摘要

()基因的突变是常染色体显性遗传帕金森病(PD)最常见的病因。突变中,p.G2019S最为常见,其遗传具有较低的外显率。有趣的是,与G2019S相关的疾病风险会因携带者的种族背景而有显著差异。虽然这表明在定义 -PD外显率方面存在遗传因素,但仅有少数变体被证明可改变携带突变患者的发病年龄,目前控制从健康状态转变为患病状态的确切细胞途径仍不清楚。鉴于这一知识空白,最近的研究也探讨了环境和生活方式因素作为 -PD潜在的修饰因素。在本文中,我们(i)描述突变携带者的临床特征,(ii)回顾与 -PD发病相关的已知基因,(iii)总结的细胞功能,特别强调与潜在外显率相关的分子机制。本节涵盖在Rab GTP酶和免疫信号传导以及线粒体稳态和动力学调节中的作用。此外,我们还探讨了关于(iv)生活方式和(v)可能影响突变外显率的环境因素的文献,以期进行进一步的暴露组学研究。最后,基于这一全面概述,我们提出了未来潜在的、和研究,这些研究可能会更好地理解在携带突变的个体中引发PD的过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11006382/08a77c52aa86/j_medgen-2022-2127_fig_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11006382/4da1e2ea7b99/j_medgen-2022-2127_fig_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11006382/08a77c52aa86/j_medgen-2022-2127_fig_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11006382/4da1e2ea7b99/j_medgen-2022-2127_fig_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11006382/08a77c52aa86/j_medgen-2022-2127_fig_002.jpg

相似文献

1
Molecular mechanisms defining penetrance of -associated Parkinson's disease.定义与帕金森病相关的外显率的分子机制。
Med Genet. 2022 Aug 12;34(2):103-116. doi: 10.1515/medgen-2022-2127. eCollection 2022 Jun.
2
Exploring environmental modifiers of LRRK2-associated Parkinson's disease penetrance: An exposomics and metagenomics pilot study on household dust.探索LRRK2相关帕金森病外显率的环境修饰因素:一项关于家庭灰尘的暴露组学和宏基因组学初步研究。
Environ Int. 2024 Dec;194:109151. doi: 10.1016/j.envint.2024.109151. Epub 2024 Nov 16.
3
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.LRRK2基因中Gly2019Ser突变在家族性帕金森病中并非完全显性:GenePD研究
BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.
4
Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.LRRK2 G2019S 变异所致帕金森病的遗传分析和自然病史。
Brain. 2024 Jun 3;147(6):1996-2008. doi: 10.1093/brain/awae073.
5
Mitochondrial Mechanisms of LRRK2 G2019S Penetrance.LRRK2基因G2019S突变外显率的线粒体机制
Front Neurol. 2020 Aug 25;11:881. doi: 10.3389/fneur.2020.00881. eCollection 2020.
6
The effect of polygenic risk score on PD risk and phenotype in G2019S and carriers.多基因风险评分对G2019S及携带者帕金森病风险和表型的影响。
J Parkinsons Dis. 2025 Mar;15(2):291-299. doi: 10.1177/1877718X241310722. Epub 2025 Jan 17.
7
The Cell Biology of LRRK2 in Parkinson's Disease.LRRK2 在帕金森病中的细胞生物学。
Mol Cell Biol. 2021 Apr 22;41(5). doi: 10.1128/MCB.00660-20.
8
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.LRRK2 GTPase 功能障碍在帕金森病发病机制中的作用。
Biochem Soc Trans. 2012 Oct;40(5):1074-9. doi: 10.1042/BST20120093.
9
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.LRRK2 p.G2019S 突变在非犹太裔个体中的外显率估计。
Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22.
10
The Effect of p.G2019S Mutation in the Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the Gene.基因 p.G2019S 突变对溶酶体水解酶活性的影响及基因 p.N370S 突变相关帕金森病的临床特征。
J Integr Neurosci. 2024 Jan 16;23(1):16. doi: 10.31083/j.jin2301016.

引用本文的文献

1
The age at onset of LRRK2 p.Gly2019Ser Parkinson's disease across ancestries and countries of origin.LRRK2基因p.Gly2019Ser突变型帕金森病在不同血统和原产国的发病年龄。
medRxiv. 2025 Jun 9:2025.06.04.25327685. doi: 10.1101/2025.06.04.25327685.
2
Microglial dynamics and neuroinflammation in prodromal and early Parkinson's disease.前驱期及早期帕金森病中的小胶质细胞动态变化与神经炎症
J Neuroinflammation. 2025 May 21;22(1):136. doi: 10.1186/s12974-025-03462-y.
3
The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson's disease.

本文引用的文献

1
Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state.人类中脑的单细胞测序揭示胶质细胞的激活和帕金森特异性神经元状态。
Brain. 2022 Apr 29;145(3):964-978. doi: 10.1093/brain/awab446.
2
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.LRRK2 型抑制剂对信号转导和线粒体自噬的影响。
Biochem J. 2021 Oct 15;478(19):3555-3573. doi: 10.1042/BCJ20210375.
3
Discovering and Summarizing Relationships Between Chemicals, Genes, Proteins, and Diseases in PubChem.在PubChem中发现并总结化学物质、基因、蛋白质和疾病之间的关系。
p.Gly2019Ser是埃及家族性和散发性帕金森病患者中常见的LRRK2致病变体。
NPJ Parkinsons Dis. 2024 Nov 6;10(1):215. doi: 10.1038/s41531-024-00826-8.
4
Analysis of rare Parkinson's disease variants in millions of people.对数百万人中的罕见帕金森病变体进行分析。
NPJ Parkinsons Dis. 2024 Jan 8;10(1):11. doi: 10.1038/s41531-023-00608-8.
5
Perspective on the current state of the LRRK2 field.对富含亮氨酸重复激酶2(LRRK2)领域当前状况的展望。
NPJ Parkinsons Dis. 2023 Jul 1;9(1):104. doi: 10.1038/s41531-023-00544-7.
Front Res Metr Anal. 2021 Jul 12;6:689059. doi: 10.3389/frma.2021.689059. eCollection 2021.
4
R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.R1441G 突变而非 G2019S 突变增强了人外周血中性粒细胞中 LRRK2 介导的 Rab10 磷酸化。
Acta Neuropathol. 2021 Sep;142(3):475-494. doi: 10.1007/s00401-021-02325-z. Epub 2021 Jun 14.
5
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.LRRK2 帕金森病修饰物的全基因组关联研究。
Ann Neurol. 2021 Jul;90(1):76-88. doi: 10.1002/ana.26094. Epub 2021 May 17.
6
An annotation database for chemicals of emerging concern in exposome research.暴露组学研究中新兴关注化学物质的注释数据库。
Environ Int. 2021 Jul;152:106511. doi: 10.1016/j.envint.2021.106511. Epub 2021 Mar 24.
7
Empowering large chemical knowledge bases for exposomics: PubChemLite meets MetFrag.为暴露组学增强大型化学知识库:PubChemLite与MetFrag的结合
J Cheminform. 2021 Mar 8;13(1):19. doi: 10.1186/s13321-021-00489-0.
8
Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort.挪威LRRK2突变携带者中的炎症性疾病。一个队列的15年随访
Front Neurosci. 2021 Jan 28;15:634666. doi: 10.3389/fnins.2021.634666. eCollection 2021.
9
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.FDA 批准的小分子蛋白激酶抑制剂的特性:2021 年更新。
Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26.
10
Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites.LRRK2 磷酸化 Rab 和 Ser910/Ser935 生物标志物位点的多重靶向质谱分析方法的建立。
Biochem J. 2021 Jan 29;478(2):299-326. doi: 10.1042/BCJ20200930.